• Explore /
  • Poster
  • / Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Richard D. Kim

H. Lee Moffitt Cancer Center, Tampa, FL

Richard D. Kim , William P. Harris , Max W. Sung , Dirk Thomas Waldschmidt , Roniel Cabrera , Udo Mueller , Flavia Menezes , Tatiane Ishida , Peter R. Galle , Anthony B. El-Khoueiry

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Hepatobiliary Cancer

Track

Hepatobiliary Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03347292

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 323)

DOI

10.1200/JCO.2021.39.3_suppl.323

Abstract #

323

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Anthony B. El-Khoueiry

First Author: Anthony B. El-Khoueiry

First Author: Jaekyung Cheon

First Author: Shun Chang Jiao